Current News

Contact | Print version | PDF version | Send article | RSS feed

Creabilis Therapeutics Appoints Anthony Wilson as its New Chief Executive Officer

18 Jun 2008 - Creabilis Therapeutics SpA announced the appointment of Tony Wilson as Chief Executive Officer with immediate effect. Mr Wilson brings to Creabilis a broad knowledge of the biotechnology and pharmaceutical industry combined with first hand experience of the dermatology sector.
 
He has over 25 years industry experience gained for the most part at Leo Pharmaceuticals a company engaged in clinical research, manufacture, marketing and sales of Leo Group products in the UK. While at Leo Pharmaceuticals Mr Wilson has been involved in the development and marketing of Dovonex and Dovobet, two of the most successful products in the history of dermatology.
 
Mr Wilson joins Creabilis from Janus Pharmaceuticals, Inc. a US-headquartered dermatology company with its lead product, luliconazole, a novel topical prescription anti-fungal product, in late stage development in the USA and Europe. Prior to that he was co-founder and CEO of Salveo Pharmaceuticals Ltd. Salveo was a speciality pharmaceutical company whose objectives were to acquire and market dermatology products in Europe.